★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Zimmer Biomet Holdings, Inc.
ZBH · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Zimmer Biomet is a global orthopedic medical-device company focused on knee and hip reconstruction, plus adjacent sports medicine/extremities/trauma and a growing robotics/digital offering. Its moat is primarily surgeon- and workflow-based: dense local sales/clinical support, consignment-heavy logistics, and procedural familiarity with instrument sets and systems. Regulatory clearance/quality systems are table-stakes barriers that still slow entrants. Q1 2026 revenue was led by Knees (~40%), S.E.T. (~27%), and Hips (~25%); older third-party industry data still shows Zimmer Biomet as a leading share holder in knees and hips worldwide (2023).
Primary segment
Knees
Market structure
Oligopoly
Market share
30.1% (reported)
HHI: 2,265
Coverage
4 segments · 5 tags
Updated 2026-06-03
Segments
Knees
Knee reconstruction implants (primary, partial, revision) plus associated instruments and orthopedic robotics/navigation
Revenue
39.7%
Structure
Oligopoly
Pricing
moderate
Share
30.1% (reported)
Peers
Hips
Hip reconstruction implants (primary and revision) plus associated instruments and orthopedic robotics/navigation
Revenue
25.1%
Structure
Oligopoly
Pricing
moderate
Share
23.5% (reported)
Peers
S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)
Sports medicine, extremities, trauma, biologics and CMFT orthopedic devices
Revenue
26.9%
Structure
Competitive
Pricing
weak
Share
—
Peers
Technology & Data, Bone Cement and Surgical
Orthopedic surgical robotics and navigation, digital care pathways/analytics, bone cement, and surgical instruments
Revenue
8.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Knees
Knee reconstruction implants (primary, partial, revision) plus associated instruments and orthopedic robotics/navigation
Revenue share computed from Q1 2026 Form 10-Q product-category table: Knees net sales $828.6M / $2.087B total.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Knee systems are embedded in surgeon preference and OR workflow; adoption requires system-specific training and familiarity (instrument sets, technique, rep support).
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Hospital standardization reduces surgeon choice
- New implant designs narrow differentiation
- Shift of volume to price-sensitive ambulatory surgery centers
Leading indicators
- Knee share trend vs SYK/JNJ/SNN
- Pricing realization (net price/mix)
- Adoption rates of new knee platforms and robotics-assisted procedures
Counterarguments
- Surgeons can switch with retraining; competitors also run extensive education programs
- Hospitals can force standardization via tenders and bundled purchasing
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Dense field support and consignment-heavy logistics improve case coverage and service reliability at the facility level.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Distributor/channel disruption
- ERP/logistics execution issues
- Hospital consolidation reduces the value of local density
Leading indicators
- Backorder/fill-rate metrics
- Rep productivity and churn
- Customer complaint / service levels
Counterarguments
- Large competitors have comparable field organizations and consignment models
- Health systems may centralize inventory and reduce vendor footprint
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Medical device regulatory clearance and quality systems create meaningful barriers to entry and slow product cycles for new competitors.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Quality failures/recalls can damage credibility and disrupt supply
- Regulatory tightening increases cost and delays innovation
Leading indicators
- Regulatory warning letters / inspection outcomes
- Recall frequency and severity
Counterarguments
- Regulatory requirements apply equally to incumbents; not a unique advantage by itself
Benchmark Pricing Power
Financial
Benchmark Pricing Power
Strength
Durability
Confidence
Evidence
Some ability to realize price (especially on differentiated systems), tempered by hospital procurement and competitive bidding.
Benchmark Pricing Power moat: definition, examples, and stocks
Erosion risks
- Aggressive tendering and reference pricing
- Competitor discounting to gain share
Leading indicators
- Gross margin trend and price/mix commentary
- GPO contract win/loss outcomes
Counterarguments
- Large joints are mature categories where purchasers can extract price concessions over time
Hips
Hip reconstruction implants (primary and revision) plus associated instruments and orthopedic robotics/navigation
Revenue share computed from Q1 2026 Form 10-Q product-category table: Hips net sales $524.1M / $2.087B total.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Hip systems are procedure-embedded; surgeon familiarity and instrument ecosystems create meaningful switching/qualification costs.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Commoditization of stems/cups
- Purchaser-driven standardization and tendering
Leading indicators
- Hip share trend vs SYK/JNJ/SNN
- Revision mix and outcomes data publications
Counterarguments
- Competitors offer comparable implant platforms and education programs
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Local field coverage and consigned inventory support case readiness and responsiveness at the account level.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Distributor instability in certain regions
- Execution issues that reduce service levels
Leading indicators
- Order fill rates and backorders
- Regional growth vs market
Counterarguments
- Incumbent peers also operate large field organizations
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Regulatory approval and ongoing quality-system compliance lengthen development cycles and add entry barriers for new products.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Regulatory tightening (e.g., post-market surveillance burdens)
- Quality remediation/inspection findings
Leading indicators
- Approval/clearance timelines for new hip systems
- Regulatory enforcement actions
Counterarguments
- Barrier affects all incumbents; differentiation comes more from commercial execution and clinical preference
Benchmark Pricing Power
Financial
Benchmark Pricing Power
Strength
Durability
Confidence
Evidence
Limited but present price realization; negotiated contracts and competitive bids cap upside.
Benchmark Pricing Power moat: definition, examples, and stocks
Erosion risks
- Hospital consolidation and stronger purchasing leverage
Leading indicators
- Gross margin and price/mix disclosure
- Competitive win/loss commentary in earnings
Counterarguments
- Large-joint categories often see long-term ASP pressure despite innovation cycles
S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)
Sports medicine, extremities, trauma, biologics and CMFT orthopedic devices
Revenue share computed from Q1 2026 Form 10-Q product-category table: S.E.T. net sales $562.2M / $2.087B total.
Scope Economies
Supply
Scope Economies
Strength
Durability
Confidence
Evidence
Broad portfolio across multiple subcategories can leverage shared sales coverage, education, and account access.
Scope Economies moat: definition, examples, and stocks
Erosion risks
- Best-of-breed specialists out-innovate in subcategories
- Private competitors with deep focus win surgeon mindshare
Leading indicators
- Growth vs category benchmarks (sports med, extremities, trauma)
- Mix shift toward faster-growing subcategories
Counterarguments
- Scope can dilute focus; category leaders may still win with superior products
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Field support and medical education help drive adoption and utilization across procedure types.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Distributor turnover in smaller markets
- Margin pressure reduces ability to fund field headcount
Leading indicators
- Salesforce productivity
- Service-level metrics (fill rates, instrument availability)
Counterarguments
- Peers also have sizable field teams; differentiation depends on execution
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Ongoing regulatory compliance and post-market obligations slow entrants and increase costs for smaller competitors.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Quality issues trigger recalls and reputational damage
Leading indicators
- Inspection outcomes and remediation spending
Counterarguments
- Regulation is necessary but not sufficient for differentiation in highly competitive subcategories
Technology & Data, Bone Cement and Surgical
Orthopedic surgical robotics and navigation, digital care pathways/analytics, bone cement, and surgical instruments
Revenue share computed from Q1 2026 Form 10-Q product-category table: Technology & Data, Bone Cement and Surgical net sales $171.8M / $2.087B total.
Ecosystem Complements
Network
Ecosystem Complements
Strength
Durability
Confidence
Evidence
Robotics/digital tools are more valuable when integrated with the broader implant/instrument ecosystem; hospitals may prefer fewer integrated platforms.
Ecosystem Complements moat: definition, examples, and stocks
Erosion risks
- Competing robotics platforms gain surgeon preference
- Hospitals standardize on a rival platform across service lines
Leading indicators
- Installed base of robotic systems
- Utilization per installed robot
- Attach rate of implants/instruments with robotic procedures
Counterarguments
- Hospitals can run multiple platforms; integration benefits may not prevent switching
- Competitors are also building end-to-end ecosystems
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Digital platforms and remote monitoring can embed the company into care pathways and value-based workflows, increasing switching friction over time.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Interoperability standards reduce lock-in
- Hospitals prefer vendor-neutral platforms
Leading indicators
- Active users on digital platforms
- Retention of facilities using digital + implant bundles
Counterarguments
- Many providers resist closed ecosystems; data portability can limit switching costs
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Robotics/software-as-medical-device features add incremental regulatory oversight and compliance burden.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Regulatory changes for AI/ML and software devices
- Cybersecurity incidents increase scrutiny and costs
Leading indicators
- Clearance/approval cadence for new modules
- Security and safety incident rate
Counterarguments
- Regulatory barriers apply broadly; market leadership depends on outcomes, usability, and economics
Evidence
We invest a significant amount of time and expense in training sales associates...
Supports qualification/training intensity and workflow reliance around product-specific usage.
Consignment sales represented approximately 85 percent of our net sales in 2025.
Consignment plus local inventory/rep coverage increases service levels and raises the operational cost of switching vendors.
All of our devices marketed in the U.S. have been cleared or approved by the FDA...
Documents the baseline regulatory hurdle and ongoing compliance burden.
Global selling prices had a minimal effect on year-over-year sales growth in 2025.
Supports the claim that some pricing actions can offset pressure, while also showing limited net pricing contribution in 2025.
Zimmer Biomet led... the knee... market with 30.1%... share...
Directly states 2023 worldwide knee implant share for Zimmer Biomet.
Showing 5 of 17 sources.
Risks & Indicators
Erosion risks
- Hospital standardization reduces surgeon choice
- New implant designs narrow differentiation
- Shift of volume to price-sensitive ambulatory surgery centers
- Distributor/channel disruption
- ERP/logistics execution issues
- Hospital consolidation reduces the value of local density
Leading indicators
- Knee share trend vs SYK/JNJ/SNN
- Pricing realization (net price/mix)
- Adoption rates of new knee platforms and robotics-assisted procedures
- Backorder/fill-rate metrics
- Rep productivity and churn
- Customer complaint / service levels
Research ZBH elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.